Translational Autoimmunity: Treatment of Autoimmune Diseases, Volume Two in the Translational Immunology series, focuses on advances in therapeutic modalities in autoimmune diseases. Efficacy and safety of not only the current biologic therapies, but also novel drug targets are discussed. Therapeutic targeting of B regulatory cells, T regulatory cells, as well as the immunomodulation effects of nanoparticles and organisms are also covered, along with our understanding and future challenges of prognostic significance of treatments in autoimmune diseases.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Professor Nima Rezaei gained his medical degree (MD) from Tehran University of Medical Sciences and subsequently obtained an MSc in Molecular and Genetic Medicine and a PhD in Clinical Immunology and Human Genetics from the University of Sheffield, UK. He also spent a short-term fellowship of Pediatric Clinical Immunology and Bone Marrow Transplantation in the Newcastle General Hospital. Professor Rezaei is now the Full Professor of Immunology and Vice Dean of Research, School of Medicine, Tehran University of Medical Sciences, and the co-founder and Head of the Research Center for Immunodeficiencies. He is also the founding President of the Universal Scientific Education and Research Network (USERN). Professor Rezaei has already been the Director of more than 55 research projects and has designed and participated in several international collaborative projects. Professor Rezaei is an editorial assistant or board member for more than 30 international journals. He has edited more than 35 international books, has presented more than 500 lectures/posters in congresses/meetings, and has published more than 1,000 scientific papers in the international journals.
The capability of the immune system-directed therapies in autoimmunity is the subject of discussion in Translational Autoimmunity: Treatment of Autoimmune Diseases. The second volume of Translational Immunology Book Series focuses on advances in therapeutic modalities in autoimmune diseases. Efficacy and safety of not only the current biologic therapies, but also novel drug targets are discussed. Therapeutic targeting of B regulatory cells, T regulatory cells, as well as immunomodulation effects of nanoparticles and organisms is also the subject of discussion in this volume. Current understanding and future challenges of prognostic significance of the treatment in autoimmune diseases are also discussed in Translational Autoimmunity: Treatment of Autoimmune Diseases.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
Anbieter: preigu, Osnabrück, Deutschland
Taschenbuch. Zustand: Neu. Translational Autoimmunity, Volume 2 | Treatment of Autoimmune Diseases | Nima Rezaei | Taschenbuch | Englisch | 2022 | Elsevier Science | EAN 9780128243909 | Verantwortliche Person für die EU: Elsevier B.V., Radarweg 29, 1043 NX AMSTERDAM, NIEDERLANDE, productsafety[at]elsevier[dot]com | Anbieter: preigu. Artikel-Nr. 120412308
Anzahl: 5 verfügbar
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
Paperback. Zustand: Brand New. 1st edition. 459 pages. 9.00x7.50x1.00 inches. In Stock. Artikel-Nr. 0128243902
Anzahl: 1 verfügbar